Marcelo Brito Telles, MD
Adult Medicine · Denton, TXNPI 1699062018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novo Nordisk at 27.8% of the total.
Across 98 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$584
- Amgen$199
- Boehringer Ingelheim$149
- Antares Pharma, Inc.$147
- Stryker$141
- Lilly USA, LLC$131
- plus $752 from 18 others
What the payments were for
- Consulting fees$251%
- Food & beverage$2,07799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $584 |
| Amgen | 11 | $199 |
| Boehringer Ingelheim | 7 | $149 |
| Antares Pharma, Inc. | 7 | $147 |
| Stryker | 2 | $141 |
| Lilly USA, LLC | 7 | $131 |
| AstraZeneca | 7 | $126 |
| Pfizer | 4 | $98 |
| Exact Sciences | 5 | $83 |
| Acella Pharmaceuticals, LLC | 3 | $57 |
| Si-bone, Inc. | 2 | $48 |
| AbbVie | 3 | $45 |
| GSK | 2 | $39 |
| Medtronic | 2 | $37 |
| Currax Pharmaceuticals LLC | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $17 |
| Merck | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$216
How this compares
$2,102 in reported general payments places this provider in the 70th percentile of 98 adult medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $79,415 |
| MounjaroTirzepatide | 25 | $34,985 |
| RybelsusSemaglutide | 13 | $31,950 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,891 |
| Liothyronine Sodium | 74 | $2,349 |
| Levothyroxine Sodium | 178 | $2,004 |
| Novolog FlexpenInsulin Aspart | 11 | $1,986 |
| Rosuvastatin Calcium | 157 | $1,950 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,316 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 18 | $1,259 |
| Gabapentin | 61 | $1,108 |
| Atorvastatin Calcium | 127 | $931 |
| Losartan Potassium | 114 | $900 |
| Metoprolol Succinate | 58 | $816 |
| Amlodipine Besylate | 132 | $810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $584 | $111,36454 claims |
| Lilly USA, LLCMounjaro | $131 | $34,98525 claims |
| GSKShingrix | $39 | $2,89113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 98 adult medicine providers in Texas.
Other adult medicine in Denton
- Deborah HornBellaire$723K
- Thomas MartensPflugerville$87K
- Sakuntalai SrinanthakumarBeaumont$48K
- Francisco Vera AdamesSpring$11K
- Latisha RoweHouston$11K
- Hong XiaoCarrollton$10K
- Mark NovasSheppard Afb$9K
- Daisy ArceWeslaco$9K
- Jeffory ThomasTexarkana$8K
- Manuel SanchezMcAllen$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.